10 results about "Quetiapine" patented technology

The invention relates to the technical field of medicines, and discloses an adeno-associated virus (AAV) injection carrying an artificial chemical genetics receptor gene sequence, and a combinatorial chemical genetics scheme formed by the adeno-associated virus injection and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention discloses a pharmaceutical composition for improving biphasic depression and a pharmaceutical preparation and application thereof, and belongs to the technical field of research and development of biphasic depression drugs, the pharmaceutical composition is composed of nicotine and a second-generation antipsychotic drug, and the second-generation antipsychotic drug is quetiapine or risperidone. Experiments prove that the combined use of the nicotine and the second-generation antipsychotic has a synergistic effect in the aspect of improving the manic behavior of biphasic depression and has a better effect of improving the biphasic depression compared with the independent use of the nicotine and the second-generation antipsychotic.

The invention discloses a composition, a method and a system for predicting the applicability of antipsychotic drugs. The invention develops a composition, a detection kit, a model construction method and a system for predicting the applicability of antipsychotic drugs on the basis of selected SNP site information. Particularly, a gene marker combination related to the curative effects of the antipsychotic drugs olanzapine, risperidone, aripiprazole and quetiapine is found by adopting a large-sample high-throughput whole-genome association analysis technology, and a corresponding mathematical model for predicting the curative effects is constructed; the model can be used for predicting the PANSS subtraction rate after the schizophrenia is treated by medication based on DNA polymorphic sites and clinical basic information of a medication user in a high, medium and low classification manner, and assists in guiding the selection of the types of the medication, so that personalized treatment of the schizophrenia patient is realized.

This invention belongs to the field of SNP site detection technology for guiding the use of second-generation antipsychotic drugs. Specifically, it relates to primer and probe combinations and applications for SNP site detection to guide personalized medication of second-generation antipsychotic drugs. The SNP site is rs17782313. The primer and probe combination includes an upstream primer SEQ ID NO:1 that specifically amplifies the wild-type T allele, an upstream primer SEQ ID NO:2 that specifically amplifies the mutant C allele, a universal downstream primer SEQ ID NO:3, a wild-type probe SEQ ID NO:4, and a mutant probe SEQ ID NO:5. This invention assesses the genetic risk of weight gain and metabolic disorders in patients with mental illness after taking second-generation antipsychotic drugs such as risperidone, quetiapine, amisulpride, and paliperidone through rapid and accurate genotyping. It features high specificity, high accuracy, speed, simplicity, and controllable cost, and can achieve rapid single-tube genotyping, providing key genetic evidence for the clinical development of personalized medication regimens.

The invention relates to a liquid formulation, in particular to a suspension, of quetiapine or a pharmaceutically acceptable salt thereof, methods for its preparation and its use in medicine, in particular for the treatment of mental, behavioural and / or mood conditions.

The application relates to the technical field of medicines, and discloses six adeno-associated virus (AAV) injection solutions carrying novel artificial chemical genetic receptor gene sequences and a combined chemical genetic scheme formed by the AAV injection solutions and a small-molecule agonist quinpirole. Compared with traditional chemical genetics, the application first uses the drug quinpirole with smaller clinical side effects as an activator to develop a novel chemical genetic system with lower drug risk. The system can effectively reduce the excitatory activity of neurons, avoid the drug risk brought by clozapine or other non-marketed traditional chemical genetic activators, and improve the feasibility of clinical transformation of the chemical genetic system. In the application of the novel or traditional chemical genetic system, the application first applies the combined treatment scheme to intervene in Parkinson's disease (PD), can inhibit the abnormal activity of STN and related circuits of PD patients, and significantly improves the symptoms of dyskinesia.

The invention relates to the technical field of medicines, and discloses six adeno-associated virus (AAV) injections carrying novel artificial chemical genetics receptor gene sequences, and a combinatorial chemical genetics scheme formed by the injections and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The present invention provides an injectable pharmaceutical composition for subcutaneous or intramuscular administration comprising quetiapine or a pharmaceutically acceptable salt thereof in an amount ranging from 10 to 50% w / w of the total weight of the composition; a biocompatible polymer selected from the group consisting of an aliphatic polyester, a glycosaminoglycan, a O-substituted cellulose derivative, or a pharmaceutically acceptable salt of any of them, and any mixture thereof; and a polar solvent; wherein the weight ratio of quetiapine or the pharmaceutically acceptable salt thereof to the biocompatible polymer is from 70:1 to 1.5:1; and the composition is a suspension. It also relates to such compositions for use in the treatment of schizophrenia and / or bipolar disorder, wherein the treatment comprises subcutaneous or intramuscular administration of the composition to a subject in need thereof. It also relates to a kit for the preparation of the injectable pharmaceutical composition.

The invention relates to a liquid formulation, in particular a suspension, of quetiapine or a pharmaceutically acceptable salt thereof, to methods for its preparation and its use in medicine, in particular for the treatment of mental, behavioral and / or mood disorders.

The present invention pertains to the technical field of pharmaceutical preparations, and provides a novel solution-type quetiapine composition for transnasal administration. In the provided composition, quetiapine is completely dissolved therein in the form of a solution and administered transnasally. Compared with oral dosage forms on the market, the provided quetiapine solution-type transnasal preparation has particularly useful pharmacokinetic and pharmacodynamic profiles. Compared with other disclosed transnasal nano-emulsion forms, the composition of the present invention still has surprising pharmacokinetic and pharmacodynamic profiles, shows good clinical application prospects, and is expected to meet unmet clinical needs. On this basis, the present invention also provides a further improved high-saturation dissolution concentration technical solution and a further improved good chemical stability technical solution for preparing the quetiapine solution-type transnasal preparation.